Home HIV	FAQ My Amedeo About	Flying Publisher
	Amedeo Prize 2008 The 21 Finalists

Drug Resistance

Free Subscription Articles published in Antivir Ther Retrieve available abstracts of 55 articles: HTML format

Single Articles

January 2008
1. PEREZ H , Vignoles M, Laufer N, Gomez A, et al
   Low rate of emergence of nevirapine and lamivudine resistance after post-partum interruption of a triple-drug regimen.
   Antivir Ther. 2008;13:135-9.
   PubMed     Related articles    Abstract available
   
   
   January 2007
2. WOO HY , Park H, Kim BI, Jeon WK, et al
   Comparison of mass spectrometric analysis and TRUGENE HBV genotyping for monitoring lamivudine resistance in chronic hepatitis B patients.
   Antivir Ther. 2007;12:7-13.
   PubMed     Related articles    Abstract available
   
   
   
3. MASCOLINI M , Boucher C, Larder B, Mellors J, et al
   Key reports from the XV International HIV Drug Resistance Workshop 2006.
   Antivir Ther. 2007;12:131-45.
   PubMed     Related articles    Abstract available
   
   
   
4. DERACHE A , Traore O, Koita V, Sylla A, et al
   Genetic diversity and drug resistance mutations in HIV type 1 from untreated patients in Bamako, Mali.
   Antivir Ther. 2007;12:123-9.
   PubMed     Related articles    Abstract available
   
   
   
5. BERTAGNOLIO S , Soto-Ramirez L, Pilon R, Rodriguez R, et al
   HIV-1 drug resistance surveillance using dried whole blood spots.
   Antivir Ther. 2007;12:107-13.
   PubMed     Related articles    Abstract available
   
   
   
6. ASBOE D , Williams IG, Goodall RL, Darbyshire JH, et al
   A virological benefit from an induction/maintenance strategy: the Forte trial.
   Antivir Ther. 2007;12:47-54.
   PubMed     Related articles    Abstract available
   
   
   
7. FUNG J , Lai CL, Yuen JC, Wong DK, et al
   Adefovir dipivoxil monotherapy and combination therapy with lamivudine for the treatment of chronic hepatitis B in an Asian population.
   Antivir Ther. 2007;12:41-6.
   PubMed     Related articles    Abstract available
   
   
   
8. STURMER M , Dauer B, Moesch M, Haberl A, et al
   Evolution of resistance mutations during low-level viral replication in HIV-1-infected patients treated with zidovudine/lamivudine/abacavir as a first-line regimen.
   Antivir Ther. 2007;12:25-30.
   PubMed     Related articles    Abstract available
   
   
   
9. LARDER B , Wang D, Revell A, Montaner J, et al
   The development of artificial neural networks to predict virological response to combination HIV therapy.
   Antivir Ther. 2007;12:15-24.
   PubMed     Related articles    Abstract available
   
   
   
10. MARCELIN AG , Flandre P, de Mendoza C, Roquebert B, et al
    Clinical validation of saquinavir/ritonavir genotypic resistance score in protease-inhibitor-experienced patients.
    Antivir Ther. 2007;12:247-52.
    PubMed     Related articles    Abstract available
    
    
    
11. ALTMANN A , Beerenwinkel N, Sing T, Savenkov I, et al
    Improved prediction of response to antiretroviral combination therapy using the genetic barrier to drug resistance.
    Antivir Ther. 2007;12:169-78.
    PubMed     Related articles    Abstract available
    
    
    
12. ZACCARELLI M , Tozzi V, Lorenzini P, Forbici F, et al
    The V118I mutation as a marker of advanced HIV infection and disease progression.
    Antivir Ther. 2007;12:163-8.
    PubMed     Related articles    Abstract available
    
    
    
13. DAM E , Lebel-Binay S, Rochas S, Thibaut L, et al
    Synergistic inhibition of protease-inhibitor-resistant HIV type 1 by saquinavir in combination with atazanavir or lopinavir.
    Antivir Ther. 2007;12:371-80.
    PubMed     Related articles    Abstract available
    
    
    
14. ILYUSHINA NA , Hoffmann E, Solomon R, Webster RG, et al
    Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice.
    Antivir Ther. 2007;12:363-70.
    PubMed     Related articles    Abstract available
    
    
    
15. QI X , Xiong S, Yang H, Miller M, et al
    In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents.
    Antivir Ther. 2007;12:355-62.
    PubMed     Related articles    Abstract available
    
    
    
16. CHAN HL , Wang H, Niu J, Chim AM, et al
    Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B: a double-blind, placebo-controlled trial.
    Antivir Ther. 2007;12:345-53.
    PubMed     Related articles    Abstract available
    
    
    
17. MATHIESEN S , Dam E, Roge B, Joergensen LB, et al
    Long-term foscarnet therapy remodels thymidine analogue mutations and alters resistance to zidovudine and lamivudine in HIV-1.
    Antivir Ther. 2007;12:335-43.
    PubMed     Related articles    Abstract available
    
    
    
18. REN GL , Fang Y, Ma HH, Lei YF, et al
    The short hairpin RNA driven by polymerase II suppresses both wild-type and lamivudine-resistant hepatitis B virus strains.
    Antivir Ther. 2007;12:865-76.
    PubMed     Related articles    Abstract available
    
    
    
19. 
    Abstracts from the XVI International HIV Drug Resistance Workshop: Basic Principles and Clinical Implications. June 12-16, 2007. Barbados, West Indies.
    Antivir Ther. 2007;12:P3-4.
    PubMed     Related articles   
    
    
    
20. DI GIAMBENEDETTO S , Brocciale L, Colafigli M, Cattani P, et al
    Declining prevalence of HIV-1 drug resistance in treatment-failing patients: a clinical cohort study.
    Antivir Ther. 2007;12:835-9.
    PubMed     Related articles    Abstract available
    
    
    
21. CHANDLER B , Detsika M, Owen A, Evans S, et al
    Effect of transporter modulation on the emergence of nelfinavir resistance in vitro.
    Antivir Ther. 2007;12:831-4.
    PubMed     Related articles    Abstract available
    
    
    
22. CHAN HL , Wong VW, Chim AM, Choi PC, et al
    Virological response to different combination regimes of peginterferon alpha-2b and lamivudine in hepatitis B e antigen positive chronic hepatitis B.
    Antivir Ther. 2007;12:815-23.
    PubMed     Related articles    Abstract available
    
    
    
23. KARATAYLI E , Karayalcin S, Karaaslan H, Kayhan H, et al
    A novel mutation pattern emerging during lamivudine treatment shows cross-resistance to adefovir dipivoxil treatment.
    Antivir Ther. 2007;12:761-8.
    PubMed     Related articles    Abstract available
    
    
    
24. DAHL G , Sandstrom A, Akerblom E, Danielson UH, et al
    Resistance profiling of hepatitis C virus protease inhibitors using full-length NS3.
    Antivir Ther. 2007;12:733-40.
    PubMed     Related articles    Abstract available
    
    
    
25. ANDREI G , Fiten P, Froeyen M, De Clercq E, et al
    DNA polymerase mutations in drug-resistant herpes simplex virus mutants determine in vivo neurovirulence and drug-enzyme interactions.
    Antivir Ther. 2007;12:719-32.
    PubMed     Related articles    Abstract available
    
    
    
26. STURMER M , Staszewski S, Doerr HW
    Quadruple nucleoside therapy with zidovudine, lamivudine, abacavir and tenofovir in the treatment of HIV.
    Antivir Ther. 2007;12:695-703.
    PubMed     Related articles    Abstract available
    
    
    
27. AOKI FY , Boivin G, Roberts N
    Influenza virus susceptibility and resistance to oseltamivir.
    Antivir Ther. 2007;12.
    PubMed     Related articles    Abstract available
    
    
    
28. CRUSAT M , de Jong MD
    Neuraminidase inhibitors and their role in avian and pandemic influenza.
    Antivir Ther. 2007;12.
    PubMed     Related articles    Abstract available
    
    
    
29. NESTOROWICZ A , Cameron S
    Key reports from the 9th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV 2007.
    Antivir Ther. 2007;12:987-98.
    PubMed     Related articles    Abstract available
    
    
    
30. UY J , Brooks JT, Baker R, Hoffman M, et al
    HIV genotypic resistance testing to optimize antiretroviral prescribing: is there room for improvement?
    Antivir Ther. 2007;12:957-62.
    PubMed     Related articles    Abstract available
    
    
    
31. LOHSE N , Jorgensen LB, Kronborg G, Moller A, et al
    Genotypic drug resistance and long-term mortality in patients with triple-class antiretroviral drug failure.
    Antivir Ther. 2007;12:909-17.
    PubMed     Related articles    Abstract available
    
    
    
32. BONNAFOUS P , Naesens L, Petrella S, Gautheret-Dejean A, et al
    Different mutations in the HHV-6 DNA polymerase gene accounting for resistance to foscarnet.
    Antivir Ther. 2007;12:877-88.
    PubMed     Related articles    Abstract available
    
    
    
33. BRUMME CJ , Harrigan PR, Preston EC, Dong WW, et al
    Transmission of drug-resistant HIV-1 from an infected individual to a caregiver.
    Antivir Ther. 2007;12:1139-44.
    PubMed     Related articles    Abstract available
    
    
    
34. VIGNOLES M , Barboni G, Agosti MR, Quarleri J, et al
    High frequency of primary mutations associated with antiretroviral drug resistance in recently diagnosed HIV-infected children.
    Antivir Ther. 2007;12:1133-7.
    PubMed     Related articles    Abstract available
    
    
    
35. LATAILLADE M , Chiarella J, Kozal MJ
    Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance.
    Antivir Ther. 2007;12:563-70.
    PubMed     Related articles    Abstract available
    
    
    
36. PEUCHANT O , Capdepont S, Ragnaud JM, Aurillac-Lavignolle V, et al
    Primary resistance to enfuvirtide (T20) in recently HIV-1 infected, antiretroviral-naive patients from the ANRS Aquitaine Cohort.
    Antivir Ther. 2007;12:559-62.
    PubMed     Related articles    Abstract available
    
    
    
37. RIDDLER SA , Jiang H, Tenorio A, Huang H, et al
    A randomized study of antiviral medication switch at lower- versus higher-switch thresholds: AIDS Clinical Trials Group Study A5115.
    Antivir Ther. 2007;12:531-41.
    PubMed     Related articles    Abstract available
    
    
    
38. DIETERICH DT
    Special considerations and treatment of patients with HBV-HIV coinfection.
    Antivir Ther. 2007;12 Suppl 3:H43-51.
    PubMed     Related articles    Abstract available
    
    
    
39. LOCARNINI S , Warner N
    Major causes of antiviral drug resistance and implications for treatment of hepatitis B virus monoinfection and coinfection with HIV.
    Antivir Ther. 2007;12 Suppl 3:H15-23.
    PubMed     Related articles    Abstract available
    
    
    
40. CHAIX ML , Desquilbet L, Descamps D, Costagliola D, et al
    Response to HAART in French patients with resistant HIV-1 treated at primary infection: ANRS Resistance Network.
    Antivir Ther. 2007;12:1305-10.
    PubMed     Related articles    Abstract available
    
    
    
41. YUEN MF , Seto WK, Chow DH, Tsui K, et al
    Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease.
    Antivir Ther. 2007;12:1295-303.
    PubMed     Related articles    Abstract available
    
    
    
42. ROQUE-AFONSO AM , Ferey MP, Ly TD, Graube A, et al
    Viral and clinical factors associated with surface gene variants among hepatitis B virus carriers.
    Antivir Ther. 2007;12:1255-63.
    PubMed     Related articles    Abstract available
    
    
    
43. VON HENTIG N , Babacon E, Staszewski S, Sturmer M, et al
    Predictive factors for response to a boosted dual HIV-protease inhibitor therapy with saquinavir and lopinavir in extensively pre-treated patients.
    Antivir Ther. 2007;12:1237-46.
    PubMed     Related articles    Abstract available
    
    
    January 2006
44. MASQUELIER B , Neau D, Boucher S, Lavignolle-Aurillac V, et al
    Antiretroviral efficacy and virological profile of a zidovudine/lamivudine/tenofovir disoproxil fumarate combination therapy in antiretroviral-naive patients.
    Antivir Ther. 2006;11:827-30.
    PubMed     Related articles    Abstract available
    
    
    
45. CHEN CH , Wang JH, Lee CM, Hung CH, et al
    Virological response and incidence of adefovir resistance in lamivudine-resistant patients treated with adefovir dipivoxil.
    Antivir Ther. 2006;11:771-8.
    PubMed     Related articles    Abstract available
    
    
    
46. DESCAMPS D , Ait-Khaled M, Craig C, Delarue S, et al
    Rare selection of the K65R mutation in antiretroviral-naive patients failing a first-line abacavir/ lamivudine-containing HAART regimen.
    Antivir Ther. 2006;11:701-5.
    PubMed     Related articles    Abstract available
    
    
    
47. MARCELIN AG , Flandre P, Furco A, Wirden M, et al
    Impact of HIV-1 reverse transcriptase polymorphism at codons 211 and 228 on virological response to didanosine.
    Antivir Ther. 2006;11:693-9.
    PubMed     Related articles    Abstract available
    
    
    
48. LAUNAY O , Duval X, Dalban C, Descamps D, et al
    Lamivudine and indinavir/ritonavir maintenance therapy in highly pretreated HIV-infected patients (Vista ANRS 109).
    Antivir Ther. 2006;11:889-99.
    PubMed     Related articles    Abstract available
    
    
    
49. VERHEYEN J , Litau E, Sing T, Daumer M, et al
    Compensatory mutations at the HIV cleavage sites p7/p1 and p1/p6-gag in therapy-naive and therapy-experienced patients.
    Antivir Ther. 2006;11:879-87.
    PubMed     Related articles    Abstract available
    
    
    
50. GREEN H , Gibb DM, Compagnucci A, Giacomet V, et al
    A randomized controlled trial of genotypic HIV drug resistance testing in HIV-1-infected children: the PERA (PENTA 8) trial.
    Antivir Ther. 2006;11:857-67.
    PubMed     Related articles    Abstract available
    
    
    
51. COURCAMBECK J , Bouzidi M, Perbost R, Jouirou B, et al
    Resistance of hepatitis C virus to NS3-4A protease inhibitors: mechanisms of drug resistance induced by R155Q, A156T, D168A and D168V mutations.
    Antivir Ther. 2006;11:847-55.
    PubMed     Related articles    Abstract available
    
    
    
52. GEROLAMI R , Bourliere M, Colson P, Halfon P, et al
    Unusual selection of rtA181V HBV mutants cross-resistant to adefovir following prolonged lamivudine monotherapy: report of two cases.
    Antivir Ther. 2006;11:1103-6.
    PubMed     Related articles    Abstract available
    
    
    
53. DING C , Wong VW, Chow KC, Chan HY, et al
    Quantitative subtyping of hepatitis B virus reveals complex dynamics of YMDD motif mutants development during long-term lamivudine therapy.
    Antivir Ther. 2006;11:1041-9.
    PubMed     Related articles    Abstract available
    
    
    
54. LINDSTROM A , Ohlis A, Huigen M, Nijhuis M, et al
    HIV-1 transmission cluster with M41L 'singleton' mutation and decreased transmission of resistance in newly diagnosed Swedish homosexual men.
    Antivir Ther. 2006;11:1031-9.
    PubMed     Related articles    Abstract available
    
    
    
55. ABED Y , Baz M, Boivin G
    Impact of neuraminidase mutations conferring influenza resistance to neuraminidase inhibitors in the N1 and N2 genetic backgrounds.
    Antivir Ther. 2006;11:971-6.
    PubMed     Related articles    Abstract available
    
    

Thank you for your interest in scientific medicine.

Amedeo is a Bernd Sebastian Kamps website.    Design: